Singapore, Aug. 8 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherap... Read More
U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07752589) titled 'Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC' on Nov. 14, 2025. Brief Summary: Lo... Read More
Singapore, Aug. 8 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Stu... Read More
U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07752290) titled 'Comparative Assessment of Adhesive PreCoated (APC) Flash-free and Conventional Brackets and ... Read More
Singapore, Aug. 8 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating t... Read More
Singapore, Aug. 8 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Plac... Read More
U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07753213) titled 'Beat Saber Exergaming and Isometric Strength in Youth Basketball Players' on Aug. 04. Brief... Read More
Singapore, Aug. 8 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Soluti... Read More
Singapore, Aug. 8 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Mo... Read More
Singapore, Aug. 8 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Mo... Read More